DaShenLin Pharmaceutical Group (603233) 주식 개요는 중국에서 의약품을 제조, 도매 및 소매하는 다센린 제약 그룹입니다. 자세히 보기603233 펀더멘털 분석스노우플레이크 점수가치 평가5/6미래 성장2/6과거 실적5/6재무 건전성5/6배당4/6강점공정 가치 추정치보다 낮은 54.8% 에서 거래수익은 매년 14.95% 증가할 것으로 예상됩니다.지난 1년간 수익이 31.8% 증가했습니다.분석가들은 주가가 31% 상승할 것이라는 데 동의합니다.위험 분석불안정한 배당 실적모든 위험 점검 보기603233 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW476,782 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA476,782 investors already sharing narrativesYour Fair ValueCN¥Current PriceCN¥18.8515.7% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture045b2016201920222025202620282031Revenue CN¥45.1bEarnings CN¥2.1bAdvancedSet Fair ValueView all narrativesDaShenLin Pharmaceutical Group Co., Ltd. 경쟁사Yifeng Pharmacy ChainSymbol: SHSE:603939Market cap: CN¥27.6bLBX Pharmacy ChainSymbol: SHSE:603883Market cap: CN¥9.7bYixintang Pharmaceutical GroupSymbol: SZSE:002727Market cap: CN¥6.7bShuYu Civilian PharmacySymbol: SZSE:301017Market cap: CN¥5.3b가격 이력 및 성과DaShenLin Pharmaceutical Group 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CN¥18.8552주 최고가CN¥21.7852주 최저가CN¥14.39베타0.541개월 변동16.72%3개월 변동0.69%1년 변동8.21%3년 변동-35.80%5년 변동-32.09%IPO 이후 변동8.23%최근 뉴스 및 업데이트Valuation Update With 7 Day Price Move • Jul 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥17.05, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 16x in the Consumer Retailing industry in China. Total loss to shareholders of 30% over the past three years.공고 • Jun 30DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 25, 2026Declared Dividend • Jun 20Dividend of CN¥0.49 announcedShareholders will receive a dividend of CN¥0.49. Ex-date: 26th June 2026 Payment date: 26th June 2026 Dividend yield will be 5.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 20% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 52% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). GM & Director Guoqiang Ke was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공고 • Apr 24DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026, at 10:00 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China공고 • Apr 23DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million.DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million on April 22, 2026. The consideration is CNY 51.73 million (all PRC stamp duties in relation to this transaction shall be borne by the Seller), representing the valuation of the target and target subsidiaries and subject to adjustment. The Consideration shall be paid by the Purchaser to the Seller in five instalments and subject to the special payment arrangement: The first instalment of CNY 4.674 million shall be paid to the Seller within 15 business days after the date of the Equity Transfer Agreement; second instalment of CNY 16.2362 million shall be paid to the Seller within 15 business days after completion of the changes to effect the Disposal, third instalment of CNY 17.0828 million shall be paid to the Seller within 15 business days after completion of operational handover matters and certain qualifications confirmed by the Purchaser, fourth instalment of CNY 2.46 million shall be paid to the Seller within 15 business days after delivery of operating systems and data to the Purchaser; and the fifth instalment of CNY 7.337 million shall be paid to the Seller within 15 business days after the earlier of (a) the first anniversary of the Closing Date; or (b) the second anniversary of the date of the equity transfer agreement. Pursuant to the Equity Transfer Agreement, an amount representing no more than 50% of the third instalment attributable to specific pharmacies may be withheld by the Purchaser and an additional CNY 3.94 million may be payable depending on the status of the lease agreement entered as prescribed by the equity transfer agreement. If any target subsidiaries are unable to operate normally following completion, the consideration shall be reduced by an amount equal to the attributed valuation of such target subsidiaries. In the event that the net assets of the target company at the closing date exceed the target net asset value of CNY 2.59 million, the consideration should be adjusted upwards to reflect the excess net asset, provided that net asset value at the closing date shall not exceed CNY 30 million and in any event, the total consideration (after any upward adjustment) shall not exceed CNY 79.14 million. As of March 31, 2026, Sipai Zhihe Technology (Guangzhou) Co., Ltd. reported total common equity of CNY 15.08 million. The completion of this transaction is contingent upon several key financial, operational, and structural conditions. Financially, the target company must maintain consolidated net assets of at least CNY 2.59 million and have accurate, compliant financial records. Operationally, all its subsidiaries must hold the necessary licenses and qualifications. Within 45 days after the date of the equity transfer agreement, the Reorganization should be completed and all of the target subsidiaries should become wholly-owned subsidiary of Sipai Zhihe Technology (Guangzhou) Co., Ltd. The net proceeds from the transaction will be applied for corporate purposes and as general working capital of the group. Ignite Capital Limited acted as financial advisor for Sipai Health.더 많은 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jul 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥17.05, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 16x in the Consumer Retailing industry in China. Total loss to shareholders of 30% over the past three years.공고 • Jun 30DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 25, 2026Declared Dividend • Jun 20Dividend of CN¥0.49 announcedShareholders will receive a dividend of CN¥0.49. Ex-date: 26th June 2026 Payment date: 26th June 2026 Dividend yield will be 5.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 20% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 52% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). GM & Director Guoqiang Ke was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공고 • Apr 24DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026, at 10:00 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China공고 • Apr 23DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million.DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million on April 22, 2026. The consideration is CNY 51.73 million (all PRC stamp duties in relation to this transaction shall be borne by the Seller), representing the valuation of the target and target subsidiaries and subject to adjustment. The Consideration shall be paid by the Purchaser to the Seller in five instalments and subject to the special payment arrangement: The first instalment of CNY 4.674 million shall be paid to the Seller within 15 business days after the date of the Equity Transfer Agreement; second instalment of CNY 16.2362 million shall be paid to the Seller within 15 business days after completion of the changes to effect the Disposal, third instalment of CNY 17.0828 million shall be paid to the Seller within 15 business days after completion of operational handover matters and certain qualifications confirmed by the Purchaser, fourth instalment of CNY 2.46 million shall be paid to the Seller within 15 business days after delivery of operating systems and data to the Purchaser; and the fifth instalment of CNY 7.337 million shall be paid to the Seller within 15 business days after the earlier of (a) the first anniversary of the Closing Date; or (b) the second anniversary of the date of the equity transfer agreement. Pursuant to the Equity Transfer Agreement, an amount representing no more than 50% of the third instalment attributable to specific pharmacies may be withheld by the Purchaser and an additional CNY 3.94 million may be payable depending on the status of the lease agreement entered as prescribed by the equity transfer agreement. If any target subsidiaries are unable to operate normally following completion, the consideration shall be reduced by an amount equal to the attributed valuation of such target subsidiaries. In the event that the net assets of the target company at the closing date exceed the target net asset value of CNY 2.59 million, the consideration should be adjusted upwards to reflect the excess net asset, provided that net asset value at the closing date shall not exceed CNY 30 million and in any event, the total consideration (after any upward adjustment) shall not exceed CNY 79.14 million. As of March 31, 2026, Sipai Zhihe Technology (Guangzhou) Co., Ltd. reported total common equity of CNY 15.08 million. The completion of this transaction is contingent upon several key financial, operational, and structural conditions. Financially, the target company must maintain consolidated net assets of at least CNY 2.59 million and have accurate, compliant financial records. Operationally, all its subsidiaries must hold the necessary licenses and qualifications. Within 45 days after the date of the equity transfer agreement, the Reorganization should be completed and all of the target subsidiaries should become wholly-owned subsidiary of Sipai Zhihe Technology (Guangzhou) Co., Ltd. The net proceeds from the transaction will be applied for corporate purposes and as general working capital of the group. Ignite Capital Limited acted as financial advisor for Sipai Health.공고 • Mar 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026공고 • Dec 26DaShenLin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026공고 • Sep 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025공고 • Jun 30DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025공고 • Apr 26DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2025DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2025, at 10:30 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China공고 • Mar 28DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025공고 • Dec 27DaShenLin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥16.98, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 14x in the Consumer Retailing industry in China. Total loss to shareholders of 33% over the past three years.Reported Earnings • Nov 05Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.22 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (down from CN¥0.22 in 3Q 2023). Revenue: CN¥6.39b (up 11% from 3Q 2023). Net income: CN¥200.5m (down 22% from 3Q 2023). Profit margin: 3.1% (down from 4.5% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.공고 • Sep 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥14.81, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 12x in the Consumer Retailing industry in China. Total loss to shareholders of 47% over the past three years.Reported Earnings • Sep 01Second quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.38 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.23 (down from CN¥0.38 in 2Q 2023). Revenue: CN¥6.59b (up 9.1% from 2Q 2023). Net income: CN¥259.1m (down 38% from 2Q 2023). Profit margin: 3.9% (down from 7.0% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.공고 • Jun 28DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2024 results on Aug 31, 2024Declared Dividend • Jun 19Dividend of CN¥0.31 announcedShareholders will receive a dividend of CN¥0.31. Ex-date: 21st June 2024 Payment date: 21st June 2024 Dividend yield will be 1.8%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (33% earnings payout ratio) and cash flows (17% cash payout ratio). The dividend has increased by an average of 5.7% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 74% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Board Change • Jun 14Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. GM & Director Guoqiang Ke was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Apr 30DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2024DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2024, at 10:30 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong ChinaReported Earnings • Apr 29First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.43 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.35 (down from CN¥0.43 in 1Q 2023). Revenue: CN¥6.75b (up 14% from 1Q 2023). Net income: CN¥398.5m (down 20% from 1Q 2023). Profit margin: 5.9% (down from 8.4% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.공고 • Mar 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.22 (up from CN¥0.18 in 3Q 2022). Revenue: CN¥5.73b (up 12% from 3Q 2022). Net income: CN¥256.9m (up 23% from 3Q 2022). Profit margin: 4.5% (up from 4.1% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 31Second quarter 2023 earnings released: EPS: CN¥0.38 (vs CN¥0.28 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.38 (up from CN¥0.28 in 2Q 2022). Revenue: CN¥6.05b (up 20% from 2Q 2022). Net income: CN¥420.7m (up 28% from 2Q 2022). Profit margin: 7.0% (up from 6.5% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.공고 • Jun 28DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2023 results on Aug 30, 2023Reported Earnings • Apr 28Full year 2022 earnings released: EPS: CN¥1.09 (vs CN¥0.83 in FY 2021)Full year 2022 results: EPS: CN¥1.09 (up from CN¥0.83 in FY 2021). Revenue: CN¥21.2b (up 27% from FY 2021). Net income: CN¥1.04b (up 31% from FY 2021). Profit margin: 4.9% (up from 4.7% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 3% per year.Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥43.56, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total returns to shareholders of 49% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥62.56 per share.Valuation Update With 7 Day Price Move • Nov 18Investor sentiment improved over the past weekAfter last week's 22% share price gain to CN¥45.38, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 25x in the Consumer Retailing industry in China. Total returns to shareholders of 55% over the past three years.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Oct 29Third quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.22 (up from CN¥0.18 in 3Q 2021). Revenue: CN¥5.10b (up 19% from 3Q 2021). Net income: CN¥209.1m (up 21% from 3Q 2021). Profit margin: 4.1% (up from 4.0% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year.Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥34.59, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 22x in the Consumer Retailing industry in China. Total returns to shareholders of 4.0% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥63.02 per share.Reported Earnings • Aug 31Second quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.32 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.34 (up from CN¥0.32 in 2Q 2021). Revenue: CN¥5.04b (up 26% from 2Q 2021). Net income: CN¥330.0m (up 8.2% from 2Q 2021). Profit margin: 6.5% (down from 7.6% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 24%, compared to a 17% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • May 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥33.25, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total returns to shareholders of 6.3% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥20.90 per share.Reported Earnings • Apr 29Full year 2021 earnings released: EPS: CN¥1.00 (vs CN¥1.35 in FY 2020)Full year 2021 results: EPS: CN¥1.00 (down from CN¥1.35 in FY 2020). Revenue: CN¥16.8b (up 15% from FY 2020). Net income: CN¥791.2m (down 26% from FY 2020). Profit margin: 4.7% (down from 7.3% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 28%, compared to a 17% growth forecast for the retail industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jan 01Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥42.11, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 26x in the Consumer Retailing industry in China. Total returns to shareholders of 110% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥23.30 per share.Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.35 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥4.30b (up 21% from 3Q 2020). Net income: CN¥172.7m (down 37% from 3Q 2020). Profit margin: 4.0% (down from 7.7% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year whereas the company’s share price has increased by 25% per year.Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.39 (vs CN¥0.41 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥4.00b (up 12% from 2Q 2020). Net income: CN¥305.1m (down 3.0% from 2Q 2020). Profit margin: 7.6% (down from 8.8% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 12Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥47.25, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 25x in the Consumer Retailing industry in China. Total returns to shareholders of 102% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥90.11 per share.Reported Earnings • Apr 20Full year 2020 earnings released: EPS CN¥1.62 (vs CN¥1.12 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥14.6b (up 31% from FY 2019). Net income: CN¥1.06b (up 51% from FY 2019). Profit margin: 7.3% (up from 6.3% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Mar 10New 90-day low: CN¥75.58The company is down 9.0% from its price of CN¥82.79 on 10 December 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.96 per share.Is New 90 Day High Low • Jan 25New 90-day high: CN¥105The company is up 22% from its price of CN¥86.12 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥64.40 per share.Valuation Update With 7 Day Price Move • Jan 17Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥89.60, the stock is trading at a trailing P/E ratio of 57.3x, up from the previous P/E ratio of 49.6x. This compares to an average P/E of 35x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 198%.Valuation Update With 7 Day Price Move • Jan 13Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥93.33, the stock is trading at a trailing P/E ratio of 59.7x, up from the previous P/E ratio of 50x. This compares to an average P/E of 34x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 208%.Is New 90 Day High Low • Jan 04New 90-day low: CN¥76.99The company is down 7.0% from its price of CN¥82.46 on 30 September 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.94 per share.Is New 90 Day High Low • Dec 19New 90-day low: CN¥78.69The company is down 2.0% from its price of CN¥80.30 on 21 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.94 per share.Is New 90 Day High Low • Nov 14New 90-day high: CN¥99.20The company is up 41% from its price of CN¥70.39 on 14 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥57.01 per share.Reported Earnings • Nov 01Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥1.01b, up 50% from the prior year. Total revenue was CN¥13.6b over the last 12 months, up 28% from the prior year.Is New 90 Day High Low • Oct 29New 90-day high: CN¥92.06The company is up 20% from its price of CN¥76.50 on 31 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥49.33 per share.주주 수익률603233CN Consumer RetailingCN 시장7D2.4%3.1%-3.9%1Y8.2%-17.9%7.3%전체 주주 수익률 보기수익률 대 산업: 603233은 지난 1년 동안 -17.9%의 수익을 기록한 CN Consumer Retailing 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: 603233은 지난 1년 동안 7.3%의 수익을 기록한 CN 시장과 동일한 성과를 보였습니다.주가 변동성Is 603233's price volatile compared to industry and market?603233 volatility603233 Average Weekly Movement5.8%Consumer Retailing Industry Average Movement5.9%Market Average Movement7.4%10% most volatile stocks in CN Market12.6%10% least volatile stocks in CN Market4.4%안정적인 주가: 603233는 지난 3개월 동안 CN 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: 603233의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트199941,141Guoqiang Kewww.dslyy.com다센린 제약 그룹은 중국에서 의약품을 제조, 도매 및 소매하는 회사입니다. 중국 및 서양 특허 의약품, 인삼 강장제 약재 및 한약재, 건강 관리 제품, 의료 장비 및 기타 상품을 제공합니다. 이 회사는 1999년에 설립되었으며 중국 광저우에 본사를 두고 있습니다.더 보기DaShenLin Pharmaceutical Group Co., Ltd. 기초 지표 요약DaShenLin Pharmaceutical Group의 순이익과 매출은 시가총액과 어떻게 비교됩니까?603233 기초 통계시가총액CN¥21.47b순이익 (TTM)CN¥1.29b매출 (TTM)CN¥27.52b16.7x주가수익비율(P/E)0.8x주가매출비율(P/S)603233는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표603233 손익계산서 (TTM)매출CN¥27.52b매출원가CN¥18.03b총이익CN¥9.49b기타 비용CN¥8.20b순이익CN¥1.29b최근 보고된 실적Mar 31, 2026다음 실적 발표일Aug 25, 2026주당순이익(EPS)1.13총이익률34.49%순이익률4.67%부채/자본 비율33.3%603233의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당5.2%현재 배당 수익률74%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/31 23:08종가2026/07/31 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스DaShenLin Pharmaceutical Group Co., Ltd.는 16명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Qianyi LiChina International Capital Corporation LimitedBinbin ZhangCitic Securities Co., Ltd.Zhijie ZhaoCLSA13명의 분석가 더 보기
Valuation Update With 7 Day Price Move • Jul 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥17.05, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 16x in the Consumer Retailing industry in China. Total loss to shareholders of 30% over the past three years.
공고 • Jun 30DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 25, 2026
Declared Dividend • Jun 20Dividend of CN¥0.49 announcedShareholders will receive a dividend of CN¥0.49. Ex-date: 26th June 2026 Payment date: 26th June 2026 Dividend yield will be 5.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 20% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 52% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). GM & Director Guoqiang Ke was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공고 • Apr 24DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026, at 10:00 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China
공고 • Apr 23DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million.DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million on April 22, 2026. The consideration is CNY 51.73 million (all PRC stamp duties in relation to this transaction shall be borne by the Seller), representing the valuation of the target and target subsidiaries and subject to adjustment. The Consideration shall be paid by the Purchaser to the Seller in five instalments and subject to the special payment arrangement: The first instalment of CNY 4.674 million shall be paid to the Seller within 15 business days after the date of the Equity Transfer Agreement; second instalment of CNY 16.2362 million shall be paid to the Seller within 15 business days after completion of the changes to effect the Disposal, third instalment of CNY 17.0828 million shall be paid to the Seller within 15 business days after completion of operational handover matters and certain qualifications confirmed by the Purchaser, fourth instalment of CNY 2.46 million shall be paid to the Seller within 15 business days after delivery of operating systems and data to the Purchaser; and the fifth instalment of CNY 7.337 million shall be paid to the Seller within 15 business days after the earlier of (a) the first anniversary of the Closing Date; or (b) the second anniversary of the date of the equity transfer agreement. Pursuant to the Equity Transfer Agreement, an amount representing no more than 50% of the third instalment attributable to specific pharmacies may be withheld by the Purchaser and an additional CNY 3.94 million may be payable depending on the status of the lease agreement entered as prescribed by the equity transfer agreement. If any target subsidiaries are unable to operate normally following completion, the consideration shall be reduced by an amount equal to the attributed valuation of such target subsidiaries. In the event that the net assets of the target company at the closing date exceed the target net asset value of CNY 2.59 million, the consideration should be adjusted upwards to reflect the excess net asset, provided that net asset value at the closing date shall not exceed CNY 30 million and in any event, the total consideration (after any upward adjustment) shall not exceed CNY 79.14 million. As of March 31, 2026, Sipai Zhihe Technology (Guangzhou) Co., Ltd. reported total common equity of CNY 15.08 million. The completion of this transaction is contingent upon several key financial, operational, and structural conditions. Financially, the target company must maintain consolidated net assets of at least CNY 2.59 million and have accurate, compliant financial records. Operationally, all its subsidiaries must hold the necessary licenses and qualifications. Within 45 days after the date of the equity transfer agreement, the Reorganization should be completed and all of the target subsidiaries should become wholly-owned subsidiary of Sipai Zhihe Technology (Guangzhou) Co., Ltd. The net proceeds from the transaction will be applied for corporate purposes and as general working capital of the group. Ignite Capital Limited acted as financial advisor for Sipai Health.
Valuation Update With 7 Day Price Move • Jul 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥17.05, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 16x in the Consumer Retailing industry in China. Total loss to shareholders of 30% over the past three years.
공고 • Jun 30DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 25, 2026
Declared Dividend • Jun 20Dividend of CN¥0.49 announcedShareholders will receive a dividend of CN¥0.49. Ex-date: 26th June 2026 Payment date: 26th June 2026 Dividend yield will be 5.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 20% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 52% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). GM & Director Guoqiang Ke was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공고 • Apr 24DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026, at 10:00 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China
공고 • Apr 23DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million.DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million on April 22, 2026. The consideration is CNY 51.73 million (all PRC stamp duties in relation to this transaction shall be borne by the Seller), representing the valuation of the target and target subsidiaries and subject to adjustment. The Consideration shall be paid by the Purchaser to the Seller in five instalments and subject to the special payment arrangement: The first instalment of CNY 4.674 million shall be paid to the Seller within 15 business days after the date of the Equity Transfer Agreement; second instalment of CNY 16.2362 million shall be paid to the Seller within 15 business days after completion of the changes to effect the Disposal, third instalment of CNY 17.0828 million shall be paid to the Seller within 15 business days after completion of operational handover matters and certain qualifications confirmed by the Purchaser, fourth instalment of CNY 2.46 million shall be paid to the Seller within 15 business days after delivery of operating systems and data to the Purchaser; and the fifth instalment of CNY 7.337 million shall be paid to the Seller within 15 business days after the earlier of (a) the first anniversary of the Closing Date; or (b) the second anniversary of the date of the equity transfer agreement. Pursuant to the Equity Transfer Agreement, an amount representing no more than 50% of the third instalment attributable to specific pharmacies may be withheld by the Purchaser and an additional CNY 3.94 million may be payable depending on the status of the lease agreement entered as prescribed by the equity transfer agreement. If any target subsidiaries are unable to operate normally following completion, the consideration shall be reduced by an amount equal to the attributed valuation of such target subsidiaries. In the event that the net assets of the target company at the closing date exceed the target net asset value of CNY 2.59 million, the consideration should be adjusted upwards to reflect the excess net asset, provided that net asset value at the closing date shall not exceed CNY 30 million and in any event, the total consideration (after any upward adjustment) shall not exceed CNY 79.14 million. As of March 31, 2026, Sipai Zhihe Technology (Guangzhou) Co., Ltd. reported total common equity of CNY 15.08 million. The completion of this transaction is contingent upon several key financial, operational, and structural conditions. Financially, the target company must maintain consolidated net assets of at least CNY 2.59 million and have accurate, compliant financial records. Operationally, all its subsidiaries must hold the necessary licenses and qualifications. Within 45 days after the date of the equity transfer agreement, the Reorganization should be completed and all of the target subsidiaries should become wholly-owned subsidiary of Sipai Zhihe Technology (Guangzhou) Co., Ltd. The net proceeds from the transaction will be applied for corporate purposes and as general working capital of the group. Ignite Capital Limited acted as financial advisor for Sipai Health.
공고 • Mar 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026
공고 • Dec 26DaShenLin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026
공고 • Sep 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025
공고 • Jun 30DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025
공고 • Apr 26DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2025DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2025, at 10:30 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China
공고 • Mar 28DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
공고 • Dec 27DaShenLin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥16.98, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 14x in the Consumer Retailing industry in China. Total loss to shareholders of 33% over the past three years.
Reported Earnings • Nov 05Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.22 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (down from CN¥0.22 in 3Q 2023). Revenue: CN¥6.39b (up 11% from 3Q 2023). Net income: CN¥200.5m (down 22% from 3Q 2023). Profit margin: 3.1% (down from 4.5% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
공고 • Sep 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥14.81, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 12x in the Consumer Retailing industry in China. Total loss to shareholders of 47% over the past three years.
Reported Earnings • Sep 01Second quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.38 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.23 (down from CN¥0.38 in 2Q 2023). Revenue: CN¥6.59b (up 9.1% from 2Q 2023). Net income: CN¥259.1m (down 38% from 2Q 2023). Profit margin: 3.9% (down from 7.0% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
공고 • Jun 28DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2024 results on Aug 31, 2024
Declared Dividend • Jun 19Dividend of CN¥0.31 announcedShareholders will receive a dividend of CN¥0.31. Ex-date: 21st June 2024 Payment date: 21st June 2024 Dividend yield will be 1.8%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (33% earnings payout ratio) and cash flows (17% cash payout ratio). The dividend has increased by an average of 5.7% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 74% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Board Change • Jun 14Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. GM & Director Guoqiang Ke was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Apr 30DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2024DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2024, at 10:30 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China
Reported Earnings • Apr 29First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.43 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.35 (down from CN¥0.43 in 1Q 2023). Revenue: CN¥6.75b (up 14% from 1Q 2023). Net income: CN¥398.5m (down 20% from 1Q 2023). Profit margin: 5.9% (down from 8.4% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
공고 • Mar 30DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.22 (up from CN¥0.18 in 3Q 2022). Revenue: CN¥5.73b (up 12% from 3Q 2022). Net income: CN¥256.9m (up 23% from 3Q 2022). Profit margin: 4.5% (up from 4.1% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 31Second quarter 2023 earnings released: EPS: CN¥0.38 (vs CN¥0.28 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.38 (up from CN¥0.28 in 2Q 2022). Revenue: CN¥6.05b (up 20% from 2Q 2022). Net income: CN¥420.7m (up 28% from 2Q 2022). Profit margin: 7.0% (up from 6.5% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
공고 • Jun 28DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2023 results on Aug 30, 2023
Reported Earnings • Apr 28Full year 2022 earnings released: EPS: CN¥1.09 (vs CN¥0.83 in FY 2021)Full year 2022 results: EPS: CN¥1.09 (up from CN¥0.83 in FY 2021). Revenue: CN¥21.2b (up 27% from FY 2021). Net income: CN¥1.04b (up 31% from FY 2021). Profit margin: 4.9% (up from 4.7% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 3% per year.
Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥43.56, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total returns to shareholders of 49% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥62.56 per share.
Valuation Update With 7 Day Price Move • Nov 18Investor sentiment improved over the past weekAfter last week's 22% share price gain to CN¥45.38, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 25x in the Consumer Retailing industry in China. Total returns to shareholders of 55% over the past three years.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 29Third quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.22 (up from CN¥0.18 in 3Q 2021). Revenue: CN¥5.10b (up 19% from 3Q 2021). Net income: CN¥209.1m (up 21% from 3Q 2021). Profit margin: 4.1% (up from 4.0% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year.
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥34.59, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 22x in the Consumer Retailing industry in China. Total returns to shareholders of 4.0% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥63.02 per share.
Reported Earnings • Aug 31Second quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.32 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.34 (up from CN¥0.32 in 2Q 2021). Revenue: CN¥5.04b (up 26% from 2Q 2021). Net income: CN¥330.0m (up 8.2% from 2Q 2021). Profit margin: 6.5% (down from 7.6% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 24%, compared to a 17% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • May 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥33.25, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total returns to shareholders of 6.3% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥20.90 per share.
Reported Earnings • Apr 29Full year 2021 earnings released: EPS: CN¥1.00 (vs CN¥1.35 in FY 2020)Full year 2021 results: EPS: CN¥1.00 (down from CN¥1.35 in FY 2020). Revenue: CN¥16.8b (up 15% from FY 2020). Net income: CN¥791.2m (down 26% from FY 2020). Profit margin: 4.7% (down from 7.3% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 28%, compared to a 17% growth forecast for the retail industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jan 01Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥42.11, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 26x in the Consumer Retailing industry in China. Total returns to shareholders of 110% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥23.30 per share.
Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.35 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥4.30b (up 21% from 3Q 2020). Net income: CN¥172.7m (down 37% from 3Q 2020). Profit margin: 4.0% (down from 7.7% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year whereas the company’s share price has increased by 25% per year.
Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.39 (vs CN¥0.41 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥4.00b (up 12% from 2Q 2020). Net income: CN¥305.1m (down 3.0% from 2Q 2020). Profit margin: 7.6% (down from 8.8% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 12Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥47.25, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 25x in the Consumer Retailing industry in China. Total returns to shareholders of 102% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥90.11 per share.
Reported Earnings • Apr 20Full year 2020 earnings released: EPS CN¥1.62 (vs CN¥1.12 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥14.6b (up 31% from FY 2019). Net income: CN¥1.06b (up 51% from FY 2019). Profit margin: 7.3% (up from 6.3% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Mar 10New 90-day low: CN¥75.58The company is down 9.0% from its price of CN¥82.79 on 10 December 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.96 per share.
Is New 90 Day High Low • Jan 25New 90-day high: CN¥105The company is up 22% from its price of CN¥86.12 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥64.40 per share.
Valuation Update With 7 Day Price Move • Jan 17Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥89.60, the stock is trading at a trailing P/E ratio of 57.3x, up from the previous P/E ratio of 49.6x. This compares to an average P/E of 35x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 198%.
Valuation Update With 7 Day Price Move • Jan 13Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥93.33, the stock is trading at a trailing P/E ratio of 59.7x, up from the previous P/E ratio of 50x. This compares to an average P/E of 34x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 208%.
Is New 90 Day High Low • Jan 04New 90-day low: CN¥76.99The company is down 7.0% from its price of CN¥82.46 on 30 September 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.94 per share.
Is New 90 Day High Low • Dec 19New 90-day low: CN¥78.69The company is down 2.0% from its price of CN¥80.30 on 21 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.94 per share.
Is New 90 Day High Low • Nov 14New 90-day high: CN¥99.20The company is up 41% from its price of CN¥70.39 on 14 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥57.01 per share.
Reported Earnings • Nov 01Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥1.01b, up 50% from the prior year. Total revenue was CN¥13.6b over the last 12 months, up 28% from the prior year.
Is New 90 Day High Low • Oct 29New 90-day high: CN¥92.06The company is up 20% from its price of CN¥76.50 on 31 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥49.33 per share.
